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Abstract Charcot–Marie–Tooth disease (CMT) is the most
common inherited peripheral neuropathy, with an estimated
prevalence of 1 in 2500. The degeneration of motor and sen-
sory nerve axons leads to motor and sensory symptoms that
progress over time and have an important impact on the daily
life of these patients. Currently, there is no curative treatment
available. Recently, we identified histone deacetylase 6
(HDAC6), which deacetylates α-tubulin, as a potential thera-
peutic target in axonal CMT (CMT2). Pharmacological inhi-
bition of the deacetylating function of HDAC6 reversed the
motor and sensory deficits in a mouse model for mutant
Bsmall heat shock protein B1^ (HSPB1)-induced CMT2 at
the behavioral and electrophysiological level. In order to
translate this potential therapeutic strategy into a clinical ap-
plication, small drug-like molecules that are potent and selec-
tive HDAC6 inhibitors are essential. To screen for these, we
developed amethod that consisted of 3 distinct phases and that
was based on the pathological findings in the mutant HSPB1-
induced CMT2 mouse model. Three different inhibitors
(ACY-738, ACY-775, and ACY-1215) were tested and dem-
onstrated to be both potent and selective HDAC6 inhibitors.
Moreover, these inhibitors increased the innervation of the
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neuromuscular junctions in the gastrocnemius muscle and
improved the motor and sensory nerve conduction,
confirming that HDAC6 inhibition is a potential therapeutic
strategy in CMT2. Furthermore, ACY-1215 is an interesting
lead molecule as it is currently tested in clinical trials for
cancer. Taken together, these results may speed up the
translation of pharmacological inhibition of HDAC6 into a
therapy against CMT2.
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Introduction
Post-translational modifications are important regulators of
protein function. Histone acetyltransferases add acetyl
groups to the lysine residues of histones, thereby altering
the structure of chromatin and changing gene expression,
and DNA replication and repair [1]. Removal of the
ε-N-acetylated lysine residue of histones is catalyzed by
the histone deacetylases (HDACs). The latter family
comprises 11 enzymes (HDACs 1–11), based on the
homology with the yeast HDACs, wherein 4 main classes
of HDACs can be distinguished: class I (HDACs 1, 2, 3,
and 8), class IIa (HDACs 4, 5, 7, and 9), class IIb (HDACs 6
and 10), and class IV (HDAC11). Apart from the zinc-
dependent HDACs, the nicotinamide dehydrogenase-
dependent enzymes are grouped as class III HDACs and
comprise the sirtuins (1–7) [2]. Although histones are the
most studied substrates of HDACs, there are also a wide
variety of nonhistone substrates, including transcription
factors, cytoskeletal proteins, metabolic enzymes, and
chaperones [3]. Therefore, HDACs are often referred to as
lysine acetylases to better indicate their substrate specificity
[4].
HDAC6 functions as the major deacetylating enzyme ofα-
tubulin [5], and is the only member of the HDAC family to
contain a C-terminal zinc-finger ubiquitin-binding domain
together with 2 catalytic domains at the N-terminus.
Acetylation of α-tubulin is important for the binding of
molecular motor proteins (kinesin family and dynein) to the
microtubules [6, 7]. Hence, decreased acetylation is suggested
to influence axonal transport dynamics. Disturbances in
axonal transport are often associated with peripheral
neuropathies [8]. Moreover, HDAC6 and alterations in
α-tubulin acetylation have been associated with several
human disorders such as Alzheimer’s disease, Parkinson’s
disease, Huntington’s disease, amyotrophic lateral sclerosis,
and Charcot–Marie–Tooth disease (CMT) [9–13].
CMT is the most common inherited peripheral neuropathy,
characterized by the progressive length-dependent
degeneration of motor and sensory nerve axons. Currently,
there is no therapy available for these patients [14]. In total,
mutations in > 50 genes have been associated with either the
demyelinating form (CMT1) or the axonal form (CMT2) of
CMT [15]. Mutations in the small heat shock protein B1
(HSPB1) gene constitute one of these underlying genetic
causes, leading to CMT2F in patients [16, 17]. Previously,
we developed and characterized a mouse model for mutant
HSPB1-induced CMT which overexpresses either wild-type
or mutant human cDNA of HSPB1 in neurons [13]. Typically,
these mice develop motor problems and sensory deficits from
the age of 6 months on that are reminiscent to CMT2F in
human patients. These defects in motor and sensory function
are due to the progressive degeneration of motor and sensory
nerve axons, demonstrated by reduced compound muscle
action potentials (CMAPs) and sensory nerve action potentials
(SNAPs). At the pathologic level, we found decreased levels
of acetylated α-tubulin in sciatic nerve [13]. In addition, the
axonal transport of mitochondria was disturbed in cultured
dorsal root ganglion (DRG) neurons from symptomatic
mutant HSPB1 mice. Interestingly, pharmacologic
inhibition of the deacetylating function of HDAC6 not
only normalized the defects seen in cultured DRG
neurons, but also reversed the motor and sensory
abnormalities and the electrophysiological defects
observed in vivo [13].
HDAC6 is an attractive target in the development of a
pharmacological therapy as mice with genetic deletion of
HDAC6 are viable and have a normal life span. Moreover,
research focusing on the development of several small-
molecule inhibitors with improved pharmacokinetic
properties (e.g., stability and blood–brain barrier
permeability) is expanding [18–21]. Already a plethora of
HDAC antagonists exist, all of which have made their way to
the market but lack isoform selectivity. Hydroxamic acids like
suberoylanilide hydroxamic acid (SAHA, also known as
varinostat), a Food and Drug Administration-approved drug,
and trichostatin A (TSA) are pan-HDAC inhibitors with affinity
for both class I and II HDACs [22]. The first HDAC6-specific
inhibitor, tubacin, was discovered in 2003 through a
multidimensional, cell-based screening of a deacetylase-
biased 1,3-dioxane library [23]. However, useful as a research
tool, tubacin was not favorable as a drug-like compound
because of its high lipophilicity, fast metabolization in vivo,
and tedious synthesis. In pursuit of high-selective and drug-
like inhibitors of HDAC6, tubastatin A, a hydroxamic acid,
was developed based on structural homology modeling
showing inhibitory capacity both in vitro and in vivo [24].
Continuing from this mile stone in the development of potent
and selective inhibitors of the deacetylating function of
HDAC6, we set up a screen to identify new small molecules
with improved pharmacological properties in the exploration of
a potential pharmacological therapy for CMT.
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The goal of this study was to identify potent and selective
inhibitors of the deacetylating function of HDAC6 as a poten-
tial pharmacological therapy for CMT. Based on the patholog-
ical and behavioral deficits found in the mutant HSPB1S135F
CMT2 mouse model, a study was conducted which consisted
of 3 distinct phases in which the candidate HDAC6 inhibitors
were tested for their potency and selectivity to inhibit
HDAC6. In a first step, the effect on the acetylation of α-
tubulin and histones was assessed in a neuronal cell line.
Second, we evaluated these inhibitors for their efficiency to
restore the mitochondrial axonal transport defects in cultured
DRG neurons from symptomatic mutant HSPB1 mice.
Finally, these HDAC6 inhibitors were tested in the mutant
HSPB1-induced CMT2 mouse model for their efficiency to
restore the motor and sensory problems in these mice. In this
study, we used ACY-738 and ACY-775, 2 recently reported
small molecules acting as HDAC6 inhibitors in the context of
an antidepressant therapy [25]. Additionally, we also tested
ACY-1215 (also known as ricolinostat), which has been dem-
onstrated to be a potent and selective HDAC6 inhibitor in
human multiple myeloma cell lines [26]. ACY-1215 is active
in the peripheral nervous system and was shown to work
synergistically in combination with bortezomib as a treatment
against multiple myeloma [26].
Materials and Methods
Cell Culture
Mouse neuroblastoma (N2a) cells (ATCC CCL-131) were
grown in a 1:1 mixture of Dulbecco's modified eagle medium
and F12 medium supplemented with glutamax (Thermo
Fisher Scientific Inc., Pittsburgh, PA, USA), 100 μg/ml strep-
tomycin, 100 U/ml penicillin (Thermo Fisher Scientific), 10%
fetal calf serum (Greiner Bio-One, Kremsmünster, Austria),
1% nonessential amino acids (Thermo Fisher Scientific), and
1.6% NaHCO3 (Thermo Fisher Scientific) at 37°C and 7.5%
CO2. To split the cells, cells were washed with Versene
(Thermo Fisher Scientific) and dissociated with 0.05%
Trypsin-EDTA (Thermo Fisher Scientific).
DRG neurons were cultured from 12-month-old Thy1.2-
HSPB1 S135F mice. The DRG neurons were dissected from
the spinal cord and kept in cold Hibernate A (Thermo Fisher
Scientific) supplemented with B27 (Thermo Fisher
Scientific), further referred to as HA/B27. To extract the
DRG neurons, the tissue was dissociated by 45min incubation
of 2 mg/ml papain and thorough resuspension until all tissue
was digested. The cell suspension was added to a gradient
solution containing 4 layers of 37%, 25%, 20%, and 15%
Optiprep (Sigma-Aldrich, St. Louis, MO, USA) in HA/B27,
and centrifuged for 15 min at 800 × g (without brake), after
which the cell suspension was washed in HA/B27. An
additional centrifugation step was performed for 4 min at
400 × g and the cells were plated in culture medium contain-
ing Neurobasal A (Thermo Fisher Scientific) supplemented
with B27 (Thermo Fisher Scientific), 200 mM L-glutamine
(Thermo Fisher Scientific), 68 ng/ml nerve growth factor
(Millipore, Bedford, MA, US), and antibiotics.
The N2a cells and DRG neurons were treated overnight at
37°C with dosages ranging from 10 nM to 2.5 μM of the
compounds or the same volume (v/v) of dimethylsulfoxide
(Sigma-Aldrich) for highest drug concentration tested.
Western Blot Analysis
Treated cells were washed with phosphate-buffered saline
(PBS) and collected using the EpiQuik Total Histone
Extraction Kit (EpiGentek, Farmingdale, NY, USA) accord-
ing to the manufacturer’s instructions. Protein concentra-
tions were determined using the microBCA kit (Thermo
Fisher Scientific) according to the manufacturer’s instruc-
tions. Before separating the samples on a 12% sodium do-
decyl sulfate–polyacrylamide electrophoresis gel, samples
containing equal amounts of protein were supplemented
with reducing sample buffer (Thermo Fisher Scientific)
and heated at 95°C for 5 min. After electrophoresis, the
proteins were transferred to a polyvinylidene difluoride
membrane (Merck Millipore, Darmstadt, Germany). The
nonspecific binding was blocked by incubation of the mem-
brane in 5% bovine serum albumin (BSA), diluted in Tris-
Buffered Saline Tween (50 mM TRIS, 150 mMNaCl, 0.1%
Tween-20; Applichem, Darmstadt, Germany) for 1 h at
room temperature followed by incubation with primary an-
tibodies overnight. The antibodies, diluted in Tris-Buffered
Saline Tween, were directed against α-tubulin (1/5000,
T6199; Sigma-Aldrich), acetylated α-tubulin (1/5000,
T6793 monoclonal; Sigma-Aldrich), glyceraldehyde 3-
phosphate dehydrogenase [1/1000, AM4300 (Ambion,
Carlsbad, CA, USA), histone H3 acetyl k9+k14 (1/1000,
9677L, Cell Signaling, Danvers, MA, USA), and histone 4
(1/1000, ab10158; Abcam, Cambridge, UK)]. The second-
ary antibodies, coupled to alkaline phosphatase (anti-mouse
or anti-rabbit, 1/5000; Sigma-Aldrich), were used to detect
the signal of the primary antibodies. Blots were visualised
by adding the enhanced chemical fluorescence substrate
(GE Healthcare, Uppsala, Sweden) and imaged with the
ImageQuant LAS 4000. A mild reblott ing buffer
(Millipore) was applied to strip the blots. ImageQuant TL
version 7.0 software was used to quantify the blots.
Immunocytochemistry
The cells were fixed by applying 4% paraformaldehyde
solution for 20 min and permeabilized with 2 mg/ml BSA
(Serva, Heidelberg, Germany) diluted in 0.2% Triton
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X-100/PBS for 10 min on ice. Nonspecific binding was
blocked by 3% BSA diluted in 0.02% Triton X-100/PBS
(blocking solution) for 30 min. Primary and secondary an-
tibodies were diluted in blocking solution. The following
primary antibodies, dilutions. and incubation times were
used: antiacetylated α-tubulin (1/5000, T6793 monoclonal;
Sigma-Aldrich), antihistone H3 acetyl k9+k14 (1/1000,
9677L; Cell Signaling), and antineuronal class III β-
tubulin (802001, 1/500, overnight; BioLegend, San
Diego, CA, USA). The following secondary antibodies,
corresponding dilutions, and incubation times were used:
donkey antimouse IgG (Alexa fluorophore-conjugated,
1/5000, 1 h; Life Technologies, Carlsbad, CA, USA) or
donkey anti-rabbit IgG (Alexa fluorophore-conjugated,
1/5000, 1 h; Life Technologies). After subsequent washing
with 1.5% BSA in 0.02% Triton X-100/PBS, the cover slips
were mounted with 4,6-diamidino-phenylindole-containing
Vectashield (Vectorlabs, Burlingame, CA, USA) to visual-
ize the nuclei. Fluorescent micrographs were taken using a
Zeiss Axio Imager M1 microscope (Car l Zeiss ,
Oberkochen, Germany) equipped with an AxioCam
MRm3 camera (Carl Zeiss).
Mice
All animals were housed under standard conditions according
to the guidelines of the University of Leuven (KU Leuven)
and the associated European guidelines (European Union
Directive 2010/63/EU for animal experiments). All mice were
bred to heterozygous state. All animal experiments were ap-
proved by the local ethical committee of the KU Leuven
(P033/2014 and P185/2012).
Genotyping of the transgenic animals was done using
KAPATaq Ready Mix (Kapa Biosystems, Wilmington, MA,
USA) and 2 sets of primers directed against the human cDNA
of HSPB1 (forward primer 5’-CAGCTGGCTGACCT
GTAGC-3’; reverse primer 5’-CTTGGCGGCAGTCT
CATCG-3’) or directed against the mouse interleukin-2 gene,
used as an internal control (forward primer 5’-CTAGGCCA
CAGAATTGAAAGATCT-3 ’ ; reverse pr imer 5 ’ -
GTAGTGGAAATTCTAGCATCATCC‐3’).
Axonal Transport Measurements
Prior to the measurements, the cultured DRG neurons were
loaded with MitoTracker Red FM (50 nM; Invitrogen,
Carlsbad, CA, USA). To visualize the mitochondria, the
MitoTracker was excited at 580 nm by a TILL Poly V light
source (Gräfelfing, Germany). During the measurements, the
DRG neurons were perfused in HEPES solution (containing
148 mM NaCl, 5 mM KCl, 0.1 mM MgCl2•1.6H2O, 10 mM
glucose, 10 mM HEPES, and 2 mM CaCl2•2.2H2O) at 37°C
by a heated gravity-fed perfusion system (Multichannel
systems, Reutlingen, Germany), and 200 images were record-
ed at 1 Hz by a cooled charge-coupled device camera
(Sensicam QE, PCO, Kelheim, Germany) using TILL
VisION. To analyze different parameters of mitochondri-
al movement, kymographs, or spatiotemporal maps were
obtained using Igor Pro (Wavemetrics, Portland, USA)
using custom-written routines based on a previous de-
scribed analysis algorithm [27].
Electrophysiology
For the nerve-conduction measurements, mice were anes-
thetized using 1% isoflurane/O2 gas inhalation and placed
on a heating pad to maintain body temperature. Using
subdermal needle electrodes (Technomed Europe,
Maastricht, the Netherlands) and a Medelec Syngery
EMG monitor (Vickers Medical, Sidcup, UK) compatible
with Synergy software (version 20.1.0.100), the CMAPs
were assessed by supramaximal stimulation (1 pulse/s,
0.1 ms stimulus duration) at the level of the sciatic notch
and recording at the gastrocnemius muscle [12]. SNAPs
were recorded by supramaximal stimulation (6 pulse/s,
0.1 ms stimulus duration) at the distal tip of the tail and
were measured 4 cm proximal in the tail [28]. For SNAP
recordings, multiple traces were averaged.
Histological Examination of Neuromuscular Junctions
Prior to dissection, the mice were euthanized by CO2 in-
halation and subsequent cervical dislocation. The gastroc-
nemius muscle was dissected and snap-frozen in liquid
nitrogen-cooled isopentane. Cryosections (20 μm) were
fixed with 4% paraformaldehyde for 10 min and rinsed
with PBS. Aspecific binding was blocked using 5% nor-
mal donkey serum (Sigma-Aldrich) diluted in PBS-0.1%
Triton X-100. Nerve axons were visualized using
antineurofilament light-chain antibody (Alexa488 conju-
gated, 8024S, 1/500, overnight incubation; Cell
Signalling) while the neuromuscular endplate was labeled
with α-bungarotoxin (Alexa555-conjugated, 1/5000, 1 h
incubation; Life Technologies). To quantify the number of
innervated neuromuscular junctions (NMJs), a least 100
junc t i on s f rom each musc l e was checked fo r
colocalization of the neurofilament light chain and α-
bungarotoxin signal. Fluorescent micrographs were taken
using a Zeiss Axio Imager M1 microscope (Carl Zeiss)
equipped with an AxioCam MRm3 camera (Carl Zeiss).
Results
In this study, we used ACY-738 and ACY-775, pyrimi-
dine hydroxyl amide small-molecule inhibitors that were
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previously profiled for their pharmacokinetic properties
and that showed nanomolar potency and selectivity for
HDAC6 over other HDACs [25]. In Table 1 , the most
important molecular and pharmacokinetic properties are
summarized [25]. The most potent compound is ACY-
738 with an IC50 value towards HDAC6 of 1.7 nM, while
ACY-775 is the most selective inhibitor (selectivity index
HDAC1/HDAC6 of 283). The third molecule, ACY-1215,
was chosen not only for its potency and selectivity to-
wards HDAC6 [26], but also because this compound is
currently tested in a phase II clinical trial for multiple
myeloma (clinicaltrails.gov identifier: NCT01323751)
[26]. Hence, positive results in this CMT2-based screen-
ing could facilitate the translation of ACY-1215 to the
clinic as a therapy for CMT2.
ACY-738 and ACY-775 are Potent and Selective HDAC6
Inhibitors in N2a Cells
In the cellular context of N2a cells, the effect of ACY-738
and ACY-775 on the acetylation status of α-tubulin and
histone 3 was assessed by Western blot (Fig. 1a). As a
pan-HDAC inhibitor, TSA enhances the acetylation of both
α-tubulin and histone 3, and therefore was used as a posi-
tive control in this screening (Fig. 1a–c). The HDAC6 in-
hibitors, ACY-738 and ACY-775, hyperacetylated α-
tubulin at a concentration of 1 μM. The histone acetylation
was not affected (Fig. 1a–c). Immunocytochemistry was
used to visualize the acetylation of α-tubulin, which is pres-
ent in the cytoplasm, and of histone 3, visible in the nucle-
us. In vehicle-treated cells, α-tubulin was mainly present in
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the deacetylated form, while histone 3 was clearly acetylat-
ed (Fig. 1a, d). Upon treatment with ACY-738 and ACY-
775, a clear enhancement of the acetylation of α-tubulin
was visible, while histone acetylation remained unaltered
(Fig. 1f–g).
A more profound insight into the pharmacokinetic proper-
ties of ACY-738 and ACY-775 on the acetylation ofα-tubulin
was obtained by establishing a dose–response curve in N2a
cells using concentrations ranging from 10 nM up to 2.5 μM.
Both ACY-738 and ACY-775 possessed a similar stimulating
activity towards α-tubulin acetylation (Table 1, Fig. 2a). At a
concentration of 100 nM, the acetylation of α-tubulin was
enhanced, reaching saturating levels at 1 μM. TSA reached
hyperacetylation of α-tubulin at 100 nM (Fig. 2a, b). This is
in contrast to ACY-738 and ACY-775, which required a
higher concentration to reach their maximal effect (Fig. 2a, b).
Mitochondrial Transport Defects are Rescued by HDAC6
Inhibitors ACY-738 and ACY-775
ACY-738 and ACY-775 were subsequently tested for their abil-
ity to restore the mitochondrial axonal transport defects seen in
DRG neurons cultured from symptomatic HSPB1S135F mice.
To assess whether ACY-738 or ACY-775 could affect acetyla-
tion of α-tubulin in primary neuronal cells, DRG neurons were
cultured from adult nontransgenic mice (NTG) and treated
overnight with the HDAC6 inhibitors (Fig. 3a–c). Acetylation
of α-tubulin was visualized by immunofluorescence (as shown
Fig. 1 ACY-738 and ACY-775 are potent and selective histone
deacetylase 6 inhibitors. (a) N2a cells were incubated with 1 μM ACY-
738, ACY-775, or trichostatin A (TSA) as a positive control. By Western
blot the acetylation of α-tubulin (acet α-tub) was assessed, as well as the
acetylation of histone 3 (acetH3). Total α-tubulin levels, glyceraldehyde
3-phosphate dehydrogenase (gapdh) and histone 4 (H4) were used as a
reference for equal loading. (b) The ratio of acetylated α-tubulin to total
tubulin levels was calculated and normalized to TSA-treated cells. One-
way analysis of variance (ANOVA); ***p < 0.0001; n = 4. (c) The ratio of
acetylated histone 3 to histone 4 levels was assessed and subsequently
normalized to vehicle-treated cells. One-way ANOVA; **p < 0.01; n = 3–
4. (d–g) Immunocytochemistry for acetylated α-tubulin (red) and acety-
lated histone 3 (green) on N2a cells treated with 1 μM TSA, ACY-738,
and ACY-775
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in Fig. 3a–c) and the intensity in the neurites of the neurons was
quantified and normalized to the length of the fluorescent signal
(Fig. 3d). In vehicle-treated DRG neurons, acetylatedα-tubulin
was already present (Fig. 3a). Upon treatment with ACY-738 or
ACY-775 the signal intensity of acetylated α-tubulin increased
significantly (Fig. 3d).
Next, DRG neurons were cultured from symptomatic
HSPB1S135F mice and treated with the highest dose (2.5 μM)
tested in NTG DRG neurons to investigate the ability of ACY-
738 and ACY-775 to restore the mitochondrial axonal transport
defects. Kymographs represent the general movement of mito-
chondria in the neurites of HSPB1S135F DRG neurons treated
with vehicle, ACY-738 or ACY-775 (Fig. 3e). Significant in-
creased motility of mitochondria and also the total number of
mitochondria within the neurites was observed compared with
vehicle-treated DRG neurons (Fig. 3f, g). Interestingly, a sig-
nificantly higher number of retrogradely transported mitochon-
dria was observed in DRG neurons treated with ACY-775 com-
pared with vehicle-treated cells (Fig. 3h).
ACY-738, ACY-775, and ACY-1215 Reverse the Motor
and Sensory Axonal Deficits in HSPB1S135F CMT2Mouse
Model
The last phase of the screening aimed to establish the effect of
HDAC6 inhibition by ACY-738 or ACY-775 on the motor
and sensory deficits of the HSPB1S135F-induced CMT2
mouse model. We included an additional HDAC6 inhibitor,
ACY-1215, in this assay as it was characterized previously
and as it is currently in clinical trials [29]. These experiments
are also an indirect measure of the pharmacodynamic proper-
ties of the different compounds.
Symptomatic HSPB1S135F mice received daily intraperito-
neal injections of ACY-738, ACY-775, or ACY-1215 for 21
days, after which nerve-conduction studies were performed in
motor and sensory nerve nerves. Vehicle-treated mice
displayed reduced CMAP and SNAP amplitudes measured
in the sciatic nerve and tail nerve, respectively (Fig. 4a, b).
The HDAC6 inhibitors, ACY-738, ACY-775, were adminis-
tered at 3 mg/kg which is an 8× lower dosage than in the
original study using tubastatin A [13]. ACY-1215 was tested
at a higher dose (30 mg/kg). All inhibitors increased the action
potential amplitudes in motor and sensory nerves (Fig. 4a, b).
After treatment, the mice were sacrificed and the gastrocne-
mius muscle was dissected to visualize reinnervation of the
NMJs. The motor endplate was labeled usingα-bungarotoxin,
while the axonal projections were identified using an antibody
recognizing neurofilament light chain. Quantifying the num-
ber of double-labeled NMJs demonstrated a significant in-
crease in the innervation of the gastrocnemius muscle upon
treatment with all three HDAC6 inhibitors (Fig. 4c, d).
Discussion
The main goal of this study was to accelerate the translation of
the beneficial effects of HDAC6 inhibition seen in a CMT2
mouse model [13] into a pharmacological therapy for patients
with CMT for which currently no treatment exists. Three py-
rimidine hydroxyl amide small molecules (ACY-738, ACY-
775, ACY-1215) were tested in a screening method based on
the behavioral and pathological abnormalities of the
HSPB1S135F-induced CMT2mouse model [13]. The chemical
structures of the tested compounds all contained a similar
functional group, which classifies them as hydroxamic acids,
and only differed in the capping group. So far, 3 small mole-
cules harboring a hydroxamic acid (vorinostat, panobinostat,
and belinostat) have been approved as anticancer agents and
these compounds are all broad-spectrum HDAC inhibitors
[30]. However, these compounds exhibit poor pharmacokinet-
ics, including rapidmetabolic degradation, and poor selectivity,
inducing off-target effects and toxicity [30]. As a consequence,
Fig. 2 Pharmacokinetic properties of ACY-738 and ACY-775 in N2a
cells. (a) Dose–response of trichostatin A (TSA), ACY-738, or ACY-
775 on acetylation of α-tubulin was established in N2a cells and
determined by Western blot. (b) Quantification of the ratio of acetylated
α-tubulin to total tubulin levels on Western blot. Values were normalized
to the effect of 2.5 μM (n = 3)
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selective HDAC inhibitors with improved pharmacokinetic
and pharmacodynamic properties are urgently needed.
In the first phase of our study, ACY-738 and ACY-775
demonstrated selective and potent inhibition towards
HDAC6. Both HDAC6 inhibitors were able to rescue
the axonal transport defects of mitochondria seen in cul-
tured DRG neurons from a mutant HSPB1–CMT2 mouse
model. ACY-775 showed a higher potency to induce α-
tubulin acetylation than ACY-738, as indicated by the
larger effect on the mitochondrial transport defects, de-
spite the higher IC50 value of ACY-775. Most important-
ly, ACY-738 and ACY-775 could also reverse the deficits
observed in the motor and sensory nerves of the CMT2
mouse model. Interestingly, symptomatic HSPB1S135F
mice only show axonal loss in the distal part of the sciatic
nerve [13]. Therefore, we examined the innervation of
NMJs in the gastrocnemius muscle after treatment with
HDAC6 inhibitors. The enhanced CMAP amplitudes
measured in the gastrocnemius muscle after treatment is
in line with histological evidence of improved innervation
of the NMJs. On the sensory side, histopathology of the
sensory nerve endings using immunofluorescent labeling
of PGP9.5, as well as β3-tubulin, was performed in trans-
verse sections of the skin of the tail, looking at the
intraepidermal nerve fiber densities. So far, we could not
observe any morphological structures and thus further in-
vestigation is needed to determine the effect of HDAC6
inhibition on the sensory nerve regeneration in relation to
the improved SNAP amplitudes.
In addition, we could confirm the positive effects of ACY-
738 and ACY-775 using ACY-1215. This selective HDAC6
inhibitor has already been extensively characterized with re-
gard to its enzymatic potency and selectivity towards HDACs.
We observed a significant effect of ACY-1215 on both the
motor and sensory defects in CMT2 mice. Currently, ACY-
1215 is tested in a phase II clinical trial for multiple myeloma,
which makes it a convenient lead molecule to be tested as a
pharmacological treatment in patients with CMT. Hence,
these positive results in this CMT2-based screening can help
to advance the translation of ACY-1215 into a new CMT2
therapy.
ACY-738, ACY-775, and ACY-1215 are all hydroxamic-
based structures. Despite the widespread use of hydroxamic
acids as HDAC inhibitors, concerns have been raised about
the potential mutagenicity of hydroxamic acids. These com-
pounds could have the ability to induce point mutations, in-
sertions, or deletions in DNA, chromosomal breakages, and/or
the rearrangement of chromosomes [30]. Molecules having
this tendency are thus potentially carcinogenic. Nevertheless,
ACY-1215 has been shown to be safe and well tolerated in a
phase I study and to beAmes-negative. As a consequence, this
HDAC6 inhibitor is an attractive molecule to treat patients
with CMT.
Pharmacologic inhibition of HDAC6 is a promising new
therapeutic target for patients with CMT and our findings add
to the growing list of ongoing preclinical and clinical research.
However, it remains to be demonstrated whether the therapeu-
tic effect of HDAC6 inhibition is only relevant for patients
with a mutation in HSPB1, or whether it can be extrapolated
to other forms of CMT2, or even to CMT1. At present, most
pharmacologic strategies focused on this demyelinating form
of CMT. Unfortunately, the beneficial effects of ascorbic acid
Fig. 3 Histone deacetylase 6 (HDAC6) inhibition using ACY-738 and
ACY-775 rescued the mitochondrial defects in dorsal root ganglion
(DRG) neurons cultured from symptomatic HSPB1
S135F
mice. (a–c)
Nontransgenic DRG neurons were incubated with 2.5 μM ACY-738 or
ACY-775. Immunocytochemical labeling of acetylated α-tubulin shows
increased immunofluorescence in neurons upon HDAC6 inhibition.
Scale bar = 40 μm. (d) The intensity of acetylated α-tubulin was
quantified in the neurites from DRG neuron cultures and corrected for
the length of the signal. All values within each experiment were
normalized to vehicle-treated cells; n = 5 with 43–61 cells per condition.
(e) Kymographs representing the axonal movement of mitochondria in
HSPB1S135F DRG neurons treated with ACY-738 or ACY-775 (2.5 μM).
Vertical lines representing stationary mitochondria and lines deflecting to
the right or left indicate anterograde or retrograde movement of
mitochondria, respectively. (f) The number of moving mitochondria per
100 μm in the neurites was quantified based on the kymographs from
HSPB1S135F DRG neurons treated with ACY-738 or ACY-775;
n = 25–35 from 3 different transgenic mice. (g) The total number of
mitochondria per 100 μm in the neurites was quantified based on the
kymographs from HSPB1S135F DRG neurons treated with ACY-738 or
ACY-775; n = 25–35 from 3 different transgenic mice. (h) Additional
analysis was performed to assess the number of anterogradely or
retrogradely moving mitochondria per 100 μm in the neurites based on
the kymographs from HSPB1S135F DRG neurons treated with ACY-738
or ACY-775; n = 3 with 7–10 cells per experiment. One-way analysis of
variance (ANOVA); *p < 0.05, ***p < 0.0001. Two-way ANOVA;
*p < 0.05, ***p < 0.0001
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observed in mouse models of CMT1 could not be reproduced
in patients with CMT1A [31–34]. The effect of neurotrophin-
3 administration on myelination and on the peripheral neurop-
athies needs further investigation before in can be translated to
the clinic [35]. The most promising therapeutic strategy at this
moment is the combinatorial therapy consisting of baclofen,
naltrexone, and sorbitol (PXT3003), which improved
myelination and nerve conduction in a CMT1A preclinical
study and was shown to be safe and well tolerated in a phase
II clinical trial. Currently, a phase III study is performed to
determine the effectiveness of PXT3003 in patients with
CMT1A [36]. Thus, further research is needed to demonstrate
the therapeutic potential of HDAC6 inhibition in CMT2 and
to add HDAC6 inhibition to the list of possible treatments for
patients with CMT2.
Interestingly, inhibition of the deacetylating function of
HDAC6 or increasing acetylation of α-tubulin have been
shown to ameliorate axonal transport deficits in models for
Parkinson’s disease and Alzheimer’s disease [11, 37].
Mitochondrial axonal transport defects are often associated
with neurodegeneration in general and with peripheral neu-
ropathies in particular [8]. Thus, investigating the effect of
HDAC6 inhibition in other peripheral neuropathies could be
another interesting route for further investigations.
HDAC6 inhibition significantly improved the mitochon-
drial axonal transport dynamics, specifically in the retrograde
direction. Kinesin requires the acetylated form of α-tubulin to
transport cargoes anterogradely along the microtubules [7].
However, the acetylated form of α-tubulin alone is not suffi-
cient to affect kinesin-1 velocity and run length in vitro [38,
Fig. 4 Histone deacetylase 6 (HDAC6) inhibition using ACY-738,
ACY-775, or ACY-1215 reversed the axonal deficits in motor and
sensory nerves and induced reinnervation of neuromuscular junction.
(a) Symptomatic (12-month-old) HSPB1S135F mice received daily
intraperitoneal injections of ACY-738, ACY-775 (3 mg/kg), ACY-1215
(30 mg/kg), or vehicle for 21 days. The compound muscle action
potential (CMAP) amplitudes were recorded from the sciatic nerve after
the treatment period. Dashed line indicates values obtained from
nontransgenic mice (NTG) mice; n = 5–8 mice. (b) The SNAP
amplitudes recorded over the sensory tail nerve after the treatment.
Dashed line indicates values obtained from NTG mice; n = 5–8 mice.
Dunnett's multiple comparison test, *p < 0.05, **p < 0.01, ***p < 0.001.
(c) After treatment, the neuromuscular junctions (NMJs) were visualized
from the gastrocnemius muscle by immunofluorescence. The motor
endplates were labeled by α-bungarotoxin and the axon terminals were
visualized by neurofilament light chain-directed antibody. Dashed line
indicates values obtained from NTG mice. (d) The number of innervated
NMJs was quantified by determining the percentage of overlap between
α-bungarotoxin and neurofilament light chain immunofluorescence.
Dashed line indicates values obtained from NTG mice; n = 5–8 mice.
Dunnett's multiple comparison test, ** p <0.01, ***p < 0.001
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39]. Therefore, increasing α-tubulin acetylation through inhi-
bition of the deacetylating function of HDAC6 does not imply
a direct effect on anterograde transport. Alternatively, HDAC6
is known to be implicated in the recruitment of
polyubiquitinated proteins to the aggresome via the dynein
motor complex [40, 41]. Mutations in HSPB1 lead to the
formation of cytoplasmic aggregates [17]. In our mutant
HSPB1-induced CMT2 mouse model, we suggest a dual hy-
pothesis where HDAC6 transports polyubiquitinated proteins,
such as mutated HSPB1, to the aggresome but, in turn,
deacetylates the microtubules causing a block of axonal trans-
port. In our DRG neuron cultures, inhibition of HDAC6 spe-
cifically stimulated the retrograde transport of mitochondria
thereby supporting our dual hypothesis. Additionally,
Calderilla-Barbosa et al. [42] proposed a model in which
HDAC6 and SQSTM-1, both recognizing polyubiquitinated
proteins, compete for the binding to dynein and where the
interaction of SQSTM-1 with dynein is necessary for proper
dynein function. This could indicate that the beneficial effect
of HDAC6 inhibition on retrograde transport is mediated
through the dynein motor.
Acetylation of α-tubulin is thus a key component in the
process of mitochondrial axonal transport and important in
neurons where axonal transport is required to meet the high-
energy demands at the synapses [43, 44]. Alterations in acet-
ylation of α-tubulin have been associated with cancer, heart
disease, inflammation, and immunity, and also with many
neurologic disorders [44]. Additionally, HDAC6 inhibition
could also improve cognitive deficits in a mouse model for
Alzheimer’s disease, has also been shown to exhibit antide-
pressant effects, and its therapeutic effect has also been dem-
onstrated in a model of ischemic brain infarction [25, 45, 46].
As a consequence, identifying HDAC6 inhibitors with im-
proved pharmacokinetic and pharmacodynamic properties
will not only be important for the development of a pharma-
cological therapy for CMT, but could also be important for a
variety of other disorders.
Further investigation and optimization of our screen-
ing method is also required, as the current method result-
ed in a limited number of compounds that could be test-
ed simultaneously. Several alternative techniques exist to
speed up and scale up the compound screening from N2a
cells to animal testing. Detection of acetylation of α-
tubulin and histones by Western blot can be substituted
by AlphaLisa [47], which, compared with Western blot,
requires no washing steps, and harbors a larger detection
window and a shorter assaying time. Technology involv-
ing induced pluripotent stem cells (iPSCs) and the dif-
ferentiation toward specific cell types is rapidly advanc-
ing [48]. Moreover, the CRISPR-Cas9 technique offers a
wide variety of possibilities in working with human cells
[49]. Starting from CMT2 patient-derived fibroblasts,
iPSC-derived DRG neurons could be used to identify
the effect of new HDAC6 inhibitors on α-tubulin acety-
lation and mitochondrial deficits. Moreover, iPSCs can
also be differentiated into motor neurons. As we can
only culture embryonic motor neurons while the Thy-
1.2 promoter is only active postnatally, we are not able
to test the effect of HDAC6 inhibitors in motor neurons
from mutant HSPB1 mice. Hence, using the iPSC-based
technology, a larger number of compounds could be test-
ed for their ability to restore the mitochondrial axonal
transport defects in both motor and sensory neurons.
In conclusion, we established a screening method
consisting of 3 different phases identifying selective and
potent HDAC6 inhibitors that can functionally restore
motor and sensory deficits in a CMT2F mouse model.
One of these inhibitors has the potential to be translated
into the clinic as it is already being tested in a clinical trial
and as it is Ames-negative. Future research will be directed
towards novel classes of HDAC6 inhibitors that carry
alternative functional motifs [50]. Moreover, studies
exploring the therapeutic potential of HDAC6 inhibition
in other genetic forms of CMT are crucial to get an idea
about the therapeutic potential of HDAC6 inhibitors in
CMT.
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